The role of oxidative stress in neuromelanin synthesis in PC12 cells

Neuroscience

Volumn 189, Issue , 2011, Pages 43-50

  He, A Y ^a   Qiu, L J ^b   Gao, Y ^a   Zhu, Y ^a   Xu, Z W ^a   Xu, J M ^a   Zhang, Z H ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b CENTRAL HOSPITAL OF WUHAN   (China)

Author keywords

Levodopa; Neuromelanin; Oxidative stress; Parkinson's disease; PC12 cells; Tyrosine hydroxylase

Indexed keywords

GLUCOSE OXIDASE; NEUROMELANIN; REACTIVE OXYGEN METABOLITE; TYROSINE 3 MONOOXYGENASE;

ARTICLE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; MELANOGENESIS; NERVE CELL; NERVE CELL DEGENERATION; OXIDATIVE STRESS; PRIORITY JOURNAL; UPREGULATION;

ANIMALS; CELL SURVIVAL; GLUCOSE OXIDASE; LEVODOPA; MELANINS; OXIDATIVE STRESS; PC12 CELLS; RATS; REACTIVE OXYGEN SPECIES; TYROSINE 3-MONOOXYGENASE;

EID: 79960918928     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2011.05.040     Document Type: Article

References (62)

1. Barden H. The histochemical relationship of neuromelanin and lipofuscin. J Neuropathol Exp Neurol 1969, 28:419-441.
2. Bush W.D., Garguilo J., Zucca F.A., Albertini A., Zecca L., Edwards G.S., Nemanich R.J., Simon J.D. The surface oxidation potential of human neuromelanin reveals a spherical architecture with a pheomelanin core and a eumelanin surface. Proc Natl Acad Sci U S A 2006, 103:14785-14789.
3. Carstam R., Brinck C., Hindemith-Augustsson A., Rorsman H., Rosengren E. The neuromelanin of the human substantia nigra. Biochim Biophys Acta 1991, 1097:152-160.
4. Chen X.C., Zhou Y.C., Chen Y., Zhu Y.G., Fang F., Chen L.M. Ginsenoside Rg1 reduces MPTP-induced substantia nigra neuron loss by suppressing oxidative stress. Acta Pharmacol Sin 2005, 26:56-62.
5. Czyzyk-Krzeska M.F., Furnari B.A., Lawson E.E., Millhorn D.E. Hypoxia increases rate of transcription and stability of tyrosine hydroxylase mRNA in pheochromocytoma (PC12) cells. J Biol Chem 1994, 269:760-764.
6. D'Amato R.J., Lipman Z.P., Snyder S.H. Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin. Science 1986, 231:987-989.
7. Déglise P., Dacher M., Dion E., Gauthier M., Armengaud C. Regional brain variations of cytochrome oxidase staining during olfactory learning in the honeybee (Apis mellifera). Behav Neurosci 2003, 117:540-547.
8. Double K.L., Ben-Shachar D., Youdimc M.B.H., Zecca L., Riederer P. Gerlachf M, Influence of neuromelanin on oxidative pathways within the human substantia nigra. Neurotoxicol Teratol 2002, 24:621-628.
9. Double K.L., Gerlach M., Schünemann V., Trautwein A.X., Zecca L., Gallorini M., Youdim M.B., Riederer P., Ben-Shachar D. Iron binding characteristics of neuromelanin of the human substantia nigra. Biochem Pharmacol 2003, 66:489-494.
10. Fedorow H., Tribl F., Halliday G., Gerlach M., Riederer P., Double K.L. Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson's disease. Prog Neurobiol 2005, 75:109-124.
11. Ferrer I., Blanco R., Carmona M., Puig B., Barrachina M., Gomez C., Ambrosio S. Active, phosphorylation-dependent mitogen-activated protein kinase (MAPK/ERK), stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), and p38 kinase expression in Parkinson's disease and dementia with Lewy bodies. J Neural Transm 2001, 108:1383-1396.
12. Finkel T., Holbrook N.J. Oxidants, oxidative stress and the biology of aging. Nature 2000, 408:239-247.
13. Fornstedt B., Rosengren E., Carlsson A. Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, dopa and dopac in the brains of eight mammalian species. Neuropharmacology 1986, 25:451-454.
14. Gammella E., Cairo G., Tacchini L. Adenosine A(2)A receptor but not HIF-1 mediates tyrosine hydroxylase induction in hypoxic PC12 cells. J Neurosci Res 2010, 88:2007-2016.
15. Greene L.A., Tischler A.S. Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci U S A 1976, 73:2424-2428.
16. Haavik J. l-DOPA is a substrate for tyrosine hydroxylase. J Neurochem 1997, 69:1720-1728.
17. Hampton M.B., Fadeel B., Orrenius S. Redox regulation of the caspases during apoptosis. Ann N Y Acad Sci 1998, 854:328-335.
18. Haycock J.W. Phosphorylation of tyrosine hydroxylase in situ at serine 8, 19, 31, and 40. J Biol Chem 1990, 265:11682-11691.
19. Herdegen T., Waetzig V. AP-1 proteins in the adult brain: facts and fiction about effectors of neuroprotection and neurodegeneration. Oncogene 2001, 20:2424-2437.
20. Hileman E.O., Liu J., Albitar M., Keating M.J., Huang P. Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemother Pharmacol 2004, 53:209-219.
21. Jin G.Z., Yin X.J., Yu X.F., Cho S.J., Lee H.S., Lee H.J., Kong K.I. Enhanced tyrosine hydroxylase expression in PC12 cells co-cultured with feline mesenchymal stem cells. J Vet Sci 2007, 8:377-382.
22. Kastner A., Hirsch E.C., Lejeune O., Javoy-Agid F., Rascol O., Agid Y. Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin contents?. J Neurochem 1992, 59:1080-1089.
23. Kim S.T., Choi J.H., Chang J.W., Kim S.W., Hwang O. Immobilization stress causes increases in tetrahydrobiopterin, dopamine, and neuromelanin and oxidative damage in the nigrostriatal system. J Neurochem 2005, 95:89-98.
24. Kim S.T., Choi J.H., Kim D.H., Hwang O. Increases in TH immunoreactivity, neuromelanin and degeneration in the substantia nigra of middle aged mice. Neurosci Lett 2006, 396:263-268.
25. Kuhn D.M., Aretha C.W., Geddes T.J. Peroxynitrite inactivation of tyrosine hydroxylase: mediation by sulfhydryl oxidation, not tyrosine nitration. J Neurosci 1999, 19:10289-10294.
26. Lindquist N.G., Larsson B.S., Lyden-Sokolowski A. Autoradiography of [14C]paraquat or [14C]diquat in frogs and mice: accumulation in neuromelanin. Neurosci Lett 1988, 93:1-6.
27. Lipman T., Tabakman R., Lazarovici P. Neuroprotective effects of the stable nitroxide compound tempol on 1-methyl-4-phenylpyridinium ion-induced neurotoxicity in the nerve growth factor-differentiated model of pheochromocytoma PC12 cells. Eur J Pharmacol 2006, 549:50-57.
28. Liu Q., Rauth A.M., Liu J., Babakhanian K., Wang X.Y., Bendayan R., Wu X.Y. Characterization of a microsphere formulation containing glucose oxidase and its in vivo efficacy in a murine solid tumor model. Pharmacol Res 2009, 110:848-856.
29. Liu Q., Shuhendler A., Cheng J., Rauth A.M., O'Brien P.J., Wu X.Y. Cytotoxicity and mechanism of action of a new ROS-generating microsphere formulation for circumventing multidrug resistance in breast cancer cells. Breast Cancer Res Treat 2010, 121:323-333.
30. Lotharius J., Barg S., Wiekop P., Lundberg C., Raymon H.K., Brundin P. Effect of mutant alpha-synucein on dopamine homeostasis in a new human mesencephalic cell line. J Biol Chem 2002, 277:38884-38894.
31. Lotharius J., Falsig J., Beek J.V., Payne S., Dringen R., Brundin P., Leist M. Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathway. J Neurosci 2005, 25:6329-6342.
32. Luo Y., Umegaki H., Wang X., Abe R., Roth G.S. Dopamine induces apoptosis through an oxidation-involved SAPK/JNK activation pathway. J Biol Chem 1998, 273:3756-3764.
33. Lyon H., Schulte E., Hoyer P.E. The correlation between uptake of methyl green and feulgen staining intensity of cell nuclei, an image analysis study. Histochem J 1989, 21:508-513.
34. McCord J.M. Superoxide radical: controversies, contradictions, and paradoxes. Proc Soc Exp Biol Med 1995, 209:112-117.
35. Mena M.A., Davila V., Bogaluvsky J., Sulzer D. A synergistic neurotrophic response to l-dihydroxyphenylalanine and nerve growth factor. Mol Pharmacol 1998, 54:678-686.
36. Miranda M., Botti D., Bonfigli A., Ventura T., Arcadi A. Tyrosinase like activity in normal substantia nigra. Gen Pharmacol 1984, 15:541-544.
37. Nankova B., Kvetnaňský R., McMahon A., Viskupic E., Hiremagalur B., Frankle G., Fukuhara K., Kopin I.J., Sabban E.L. Induction of tyrosine hydroxylase gene expression by a nonneuronal nonpituitary-mediated mechanism in immobilization stress. Proc Natl Acad Sci U S A 1994, 91:5937-5941.
38. Nankova B.B., Sabban E.L. Multiple signalling pathways exist in the stress-triggered regulation of gene expression for catecholamine biosynthetic enzymes and several neuropeptides in the rat adrenal medulla. Acta Physiol Scand 1999, 167:1-9.
39. Naoi M., Maruyama W., Dostert P. Binding of 1,2 (N)-dimethyl-6,7-dihydroxy -isoquinolinium ion to melanin: effects of ferrous and ferric ion on the binding. Neurosci Lett 1994, 171:9-12.
40. Offen D., Ziv I., Barzilai A., Gorodin S., Glater E., Hochman A., Melamed E. Dopaminemelanin induces apoptosis in PC12 cells; possible implications for the etiology of Parkinson's disease. Neurochem Int 1997, 31:207-216.
41. Offen D., Ziv I., Sternin H., Melamed E., Hochman A. Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease. Exp Neurol 1996, 141:32-39.
42. Okun M.R., Donnelan B., Edelstein L.M., Lever W.F., Or N. Peroxidase-dependent oxidation of tyrosine or dopa to melanin in neurons. Histochemie 1971, 25:289-296.
43. Östergren A., Annas A., Skog K., Lindquist N.G., Brittebo E.B. Long-term retention of neurotoxic beta-carbolines in brain neuromelanin. J Neural Transm 2004, 111:141-157.
44. Östergren A., Svensson A.L., Lindquist N.G., Brittebo E.B. Dopamine melanin-loaded PC12 cells: a model for studies on pigmented neurons. Pigment Cell Res 2005, 18:306-314.
45. Parker A., Smith M.D. Immunohistochemical detection of cytokines and cell adhesion molecules in the synovial membrane. Methods Find Exp Clin Pharmacol 1999, 21:311-319.
46. Posser T., Franco J.L., Bobrovskaya L., Leal R.B., Dickson P.W., Dunkley P.R. Manganese induces sustained Ser40 phosphorylation and activation of tyrosine hydroxylase in PC12 cells. J Neurochem 2009, 110:848-856.
47. Pothos E., Desmond M., Sulzer D. l-3,4-dihydroxyphenylalanine increases the quantal size of exocytic dopamine release in vitro. J Neurochem 1996, 66:629-636.
48. Qu W., Fan L., Kim Y.C., Ishikawa S., Iguchi-Ariga S.M.M., Pu X.P., Ariga H. Kaempferol derivatives prevent oxidative stress-induced cell death in a DJ-1-dependent manner. J Pharmacol Sci 2009, 110:191-200.
49. Rodgers A.D., Curzon G. Melanin formation by human brain in vitro. J Neurochem 1975, 24:1123-1129.
50. Rorive S., Eddafali B., Fernandez S., Decaestecker C., André S., Kaltner H., Kuwabara I., Liu F.T., Gabius H.J., Kiss R., Salmon I. Changes in galectin-7 and cytokeratin-19 expression during the progression of malignancy in thyroid tumors: diagnostic and biological implications. Mod Pathol 2002, 15:1294-1301.
51. Royall J.A., Ischiropoulos H. Evaluation of 2',7'-dichlorofluorescin and dihydrorhodamine 123 as fluorescent probes for intracellular H2O2 in cultured endothelial cells. Arch Biochem Biophys 1993, 302:348-355.
52. Shim J.S., Kim H.G., Ju M.S., Choi J.G., Jeong S.Y., Oh M.S. Effects of the hook of Uncaria rhynchophylla on neurotoxicity in the 6-hydroxydopamine model of Parkinson's disease. J Ethnopharmacol 2009, 126:361-365.
53. Sulzer D., Bogulavsky J., Larsen K.E., Behr G., Karatekin E., Kleinman M.H., Nicholas T., David K., Edwardsi R.H., Greene L.A., Zecca L. Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc Natl Acad Sci U S A 2000, 97:11869-11874.
54. Tas S.W., Adriaansen J., Hajji N., Bakker A.C., Firestein G.S., Vervoordeldonk M.J., Tak P.P. Amelioration of arthritis by intraarticular dominant negative IKK gene therapy using adeno-associated virus type 5. Hum Gene Ther 2006, 17:821-832.
55. Youdim M.B., Ben-Shachar D., Riederer P. The enigma of neuromelanin in Parkinson's disease sub-stantia nigra. J Neural Transm 1994, 43:113-122.
56. Zecca L., Fariello R., Riederer P., Sulzer D., Gatti A., Tampellini D. The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson's disease. FEBS Lett 2002, 510:216-220.
57. Zecca L., Pietra R., Goj C., Mecacci C., Radice D., Sabbioni E. Iron and other metals in neuromelanin, substantia nigra and putamen of human brain. J Neurochem 1994, 62:1097-1100.
58. Zecca L., Tampellini D., Gatti A., Crippa R., Eisner M., Sulzer D., Ito S., Fariello R., Gallorini M. The neuromelanin of human substantia nigra and its interaction with metals. J Neural Transm 2002, 109:663-672.
59. Zecca L., Zucca F.A., Wilms H., Sulzer D. Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics. Trends Neurosci 2003, 26:578-580.
60. Zhang W., Phillips K., Wielgus A., Liu J., Albertini A., Zucca F.A., Faust R., Qian S.Y., Miller D.S., Chignell C.F., Wilson B., Jackson-Lewis V., Przedborski S., Joset D., Loike J., Hong J.S., Sulzer D., Zecca L. Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson's disease. Neurotox Res 2011, 19:63-72.
61. Zigmond M.J., Acheson A.L., Stachowiak M.K., Stricker E.M. Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical parkinsonism. Arch Neurol 1984, 41:856-861.
62. Zucca F.A., Giaveri G., Gallorini M., Albertini A., Toscani M., Pezzoli G., Lucius R., Wilms H., Sulzer D., Ito S., Wakamatsu K., Zecca L. The neuromelanin of human substantia nigra: physiological and pathogenic aspects. Pigment Cell Res 2004, 17:610-617.